| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Ajit Varki | |
| P2860 | cites work | Safety and efficacy of long-term oral anticoagulation in cancer patients | Q69745458 |
| Heparin | Q70147507 | ||
| Tumor shedding and coagulation | Q70662680 | ||
| Continuous subcutaneous heparin infusion for treatment of Trousseau's syndrome | Q70783654 | ||
| Prospective study of CAM 17.1/WGA mucin assay for serological diagnosis of pancreatic cancer | Q73073915 | ||
| The potential mechanism for the effect of heparin on tissue plasminogen activator-mediated plasminogen activation | Q73531165 | ||
| Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial | Q80079991 | ||
| Hypercoagulability preceding cancer. The iron hypothesis | Q81479287 | ||
| The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo | Q82769249 | ||
| Trousseau's syndrome. Devastating coagulopathy in the absence of heparin | Q93627535 | ||
| Circulating membrane vesicles in leukemic blood | Q93630245 | ||
| Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis | Q24529958 | ||
| Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis | Q24630993 | ||
| Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans | Q28205943 | ||
| Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2002. A 61-year-old man with headache and multiple infarcts | Q28206661 | ||
| Trousseau's syndrome | Q28259899 | ||
| Synthesis and secretion of Muc4/sialomucin complex: implication of intracellular proteolysis | Q28575052 | ||
| Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. | Q30670385 | ||
| Multiple hepatic receptors cooperate to eliminate secretory mucins aberrantly entering the bloodstream: are circulating cancer mucins the "tip of the iceberg"? | Q33234338 | ||
| Activation of blood coagulation in cancer: Trousseau's syndrome revisited. | Q33478010 | ||
| Coagulopathies of liver disease. | Q33490578 | ||
| Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features | Q33493746 | ||
| Preparation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2 | Q68324058 | ||
| Cancer procoagulant in human tumor cells: evidence from melanoma patients | Q68915717 | ||
| The P-selectin, tissue factor, coagulation triad | Q36230814 | ||
| P-selectin deficiency attenuates tumor growth and metastasis | Q36257237 | ||
| A functional role for hemostasis in early cancer development | Q36276486 | ||
| Tissue factor in cancer and angiogenesis: the molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy | Q36396873 | ||
| The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology | Q36511032 | ||
| Mechanisms of cancer-induced thrombosis in cancer | Q36541440 | ||
| Thrombosis as a harbinger of cancer | Q36556450 | ||
| A factor X-activating cysteine protease from malignant tissue | Q36999974 | ||
| Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation | Q38314015 | ||
| Differential metastasis inhibition by clinically relevant levels of heparins--correlation with selectin inhibition, not antithrombotic activity | Q38320347 | ||
| Contribution of basic residues of the D and H helices in heparin binding to protein C inhibitor | Q38335986 | ||
| Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents | Q39799215 | ||
| Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas | Q39886779 | ||
| Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis | Q40502054 | ||
| Coagulation disorders in cancer | Q41033283 | ||
| P-selectin induction of tissue factor biosynthesis and expression | Q41199026 | ||
| Mucin glycoproteins in neoplasia | Q41204090 | ||
| Secreted MUC1 mucins lacking their cytoplasmic part and carrying sialyl-Lewis a and x epitopes from a tumor cell line and sera of colon carcinoma patients can inhibit HL-60 leukocyte adhesion to E-selectin-expressing endothelial cells | Q41215213 | ||
| Characterization of the major sialyl-Lex-positive mucins present in colon, colon carcinoma, and sera of patients with colorectal cancer | Q41369397 | ||
| Calcium-Dependent Heparin-Like Ligands For L-Selectin in Nonlymphoid Endothelial Cells | Q41541458 | ||
| Distinct selectin ligands on colon carcinoma mucins can mediate pathological interactions among platelets, leukocytes, and endothelium | Q41683514 | ||
| Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism | Q42647384 | ||
| Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study | Q44086372 | ||
| Profiles of Lewisx-containing glycoproteins and glycolipids in sera of patients with adenocarcinoma | Q44387332 | ||
| Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). | Q44895898 | ||
| Properties of proteins in cancer procoagulant preparations that are detected by anti-tissue factor antibodies | Q44972853 | ||
| Malignancies, prothrombotic mutations, and the risk of venous thrombosis | Q45249091 | ||
| The activation of coagulation by extracts of mucus: a possible pathway of intravascular coagulation accompanying adenocarcinomas | Q45855273 | ||
| Immunohistochemical identification of tissue factor in solid tumors | Q46073640 | ||
| Endothelial heparan sulfate proteoglycans that bind to L-selectin have glucosamine residues with unsubstituted amino groups | Q46519756 | ||
| Cancer procoagulant in patients with adenocarcinomas. | Q46790662 | ||
| Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma | Q47200323 | ||
| Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins | Q47237158 | ||
| Differential effects of low molecular weight heparin and unfractionated heparin on circulating levels of antithrombin and tissue factor pathway inhibitor (TFPI): a possible mechanism for difference in therapeutic efficacy | Q47281554 | ||
| Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: evidence for a difference in antithrombotic action | Q47284848 | ||
| Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome | Q47298925 | ||
| Low-molecular-weight heparin in the management of Trousseau's syndrome | Q47303117 | ||
| Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction | Q47820598 | ||
| Tumors, mucus production, and hypercoagulability | Q48595231 | ||
| Malignancy, thrombosis and Trousseau: the case for an eponym. | Q48674406 | ||
| Increased incidence of neoplasia of the digestive tract in men with persistent activation of the coagulant pathway. | Q50754008 | ||
| Decision analysis for cancer screening in idiopathic venous thromboembolism. | Q53566113 | ||
| Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. | Q55061156 | ||
| Hypercoagulability preceding cancer | Q57300727 | ||
| The MET oncogene drives a genetic programme linking cancer to haemostasis | Q58165024 | ||
| Human breast and colon carcinomas express cysteine proteinase activities with pro-aggregating and pro-coagulant properties | Q59697349 | ||
| Non-anticoagulant effects of heparin in carcinoma metastasis and Trousseau's syndrome. | Q64902121 | ||
| Occurrence of fibrin and tissue factor antigen in human small cell carcinoma of the lung | Q67302261 | ||
| Functional interaction of plasminogen activator inhibitor type 1 (PAI-1) and heparin | Q67679504 | ||
| Venous thromboembolism in malignancy and malignancy in venous thromboembolism | Q33539576 | ||
| Treatment of venous thromboembolism in cancer patients | Q33539582 | ||
| Markedly elevated CA125 in hepatic cirrhosis: two case illustrations and review of the literature | Q33541506 | ||
| Usefulness of novel tumour markers | Q33705248 | ||
| The structure and assembly of secreted mucins | Q33763293 | ||
| Production and chemical processing of low molecular weight heparins. | Q33767613 | ||
| Mucin-type O-glycans and leukosialin | Q33778415 | ||
| What else can 'Heparin' do? | Q33813637 | ||
| MUC1: the polymorphic appearance of a human mucin | Q33891616 | ||
| Tissue factor on the loose | Q34090266 | ||
| Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy) and metastasis | Q34164159 | ||
| Inflammatory roles of P-selectin | Q34169805 | ||
| Physiological function of tissue factor pathway inhibitor and interaction with heparins | Q34184481 | ||
| Molecular diversity of heparan sulfate | Q34310374 | ||
| The prothrombotic state in cancer: pathogenic mechanisms | Q34325216 | ||
| Molecular basis for the relationship between thrombosis and cancer | Q34342948 | ||
| Venous thrombosis in inflammatory bowel disease | Q34425376 | ||
| Order out of complexity--protein structures that interact with heparin | Q34489551 | ||
| Cancer and the prothrombotic state | Q34573761 | ||
| Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans | Q34581960 | ||
| Therapeutic equivalency of low-molecular-weight heparins | Q34648639 | ||
| Cancer and thromboembolic disease: pathogenic mechanisms | Q34863041 | ||
| Managing thromboembolic disease in the cancer patient: efficacy and safety of antithrombotic treatment options in patients with cancer | Q34863092 | ||
| Heparin-protein interactions | Q35030190 | ||
| Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment | Q35036888 | ||
| Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation | Q35081869 | ||
| Low-molecular-weight heparin in oncology. | Q35202570 | ||
| Tissue factor as a tumor procoagulant | Q35477714 | ||
| Tissue factor pathway inhibitor and heparin | Q35533547 | ||
| Molecular interactions between heparin cofactor II and thrombin | Q35557166 | ||
| The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development | Q35566170 | ||
| Tumor sialomucin complexes as tumor antigens and modulators of cellular interactions and proliferation | Q35654792 | ||
| Low-molecular-weight heparin in thrombosis and cancer | Q35746197 | ||
| The heparins and cancer: review of clinical trials and biological properties | Q36021780 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cell biology | Q7141 |
| Trousseau's syndrome | Q15401621 | ||
| P304 | page(s) | 1723-9 | |
| P577 | publication date | 2007-09-15 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Trousseau's syndrome: multiple definitions and multiple mechanisms | |
| P478 | volume | 110 |
| Q58731687 | "Recurrent multiple cerebral infarctions related to the progression of adenomyosis: a case report" |
| Q92053574 | A case of Trousseau's syndrome due to intrahepatic cholangiocarcinoma with an extremely high level of CA19-9 |
| Q90467139 | A case of anticoagulant treatment-resistant Trousseau syndrome controlled by treatment of the underlying lung adenocarcinoma: Utility of monitoring D-dimer levels |
| Q94597086 | A case of successful anesthetic management in a patient with Trousseau's syndrome who underwent surgery for malignant ovarian tumor |
| Q38145567 | A platelet-inspired paradigm for nanomedicine targeted to multiple diseases |
| Q36949458 | A platelet-mimetic paradigm for metastasis-targeted nanomedicine platforms |
| Q33419224 | A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center |
| Q52651810 | Acantholytic squamous cell carcinoma of the lung with marked lymphogenous metastases and high titers of myeloperoxidase-antineutrophil cytoplasmic antibodies: a case report. |
| Q26998742 | Activation of blood coagulation in cancer: implications for tumour progression |
| Q47684875 | Acute Arterial Thrombosis during Postoperative Adjuvant Cisplatin-based Chemotherapy for Completely Resected Lung Adenocarcinoma |
| Q37616839 | Acute Bilateral Renal and Splenic Infarctions Occurring during Chemotherapy for Lung Cancer |
| Q36721740 | Acute Myocardial Infarction in Association with Occult Ovarian Cancer |
| Q46085246 | Acute ischaemic cerebrovascular attack secondary to infusional 5-fluoruracil and cisplatin in a patient with advanced gastric cancer |
| Q37581540 | Altered tumor-cell glycosylation promotes metastasis |
| Q53550880 | An Unusual Case of Gastric Cancer with Bone Marrow Metastases and Embolic Phenomena as Initial Presentation. |
| Q26796955 | Anti-angiogenesis or pro-angiogenesis for cancer treatment: focus on drug distribution |
| Q93145673 | Anticoagulants for cancer-associated ischemic stroke |
| Q26740812 | Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis |
| Q37844474 | Anticoagulation in the management of venous thromboembolism in the cancer patient |
| Q24633053 | Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q64974314 | Aortic Mural Thrombus in the Non-atherosclerotic Aorta of Patients with Multiple Hypercoagulable Factors. |
| Q39524033 | Ascidian dermatan sulfates attenuate metastasis, inflammation and thrombosis by inhibition of P-selectin. |
| Q37393394 | Assessing risk of venous thromboembolism in the patient with cancer. |
| Q57464087 | Bevacizumab-induced Aortic Arterial Thrombosis |
| Q55332820 | Bladder squamous cell cancer accompanied by Trousseau's syndrome: a case report. |
| Q50439917 | Blue toe syndrome and sunitinib |
| Q34657739 | Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets |
| Q39235761 | Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer |
| Q58784478 | Cancer and Thrombosis-New Insights |
| Q37558436 | Cancer and Thrombosis: The Platelet Perspective. |
| Q33763866 | Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management |
| Q98183379 | Cancer animal models in thrombosis research |
| Q35810537 | Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins |
| Q61443225 | Cancer cell-derived immunoglobulin G activates platelets by binding to platelet FcγRIIa |
| Q37393386 | Cancer, clots and consensus: new understanding of an old problem. |
| Q51496815 | Cancer-Associated Thrombosis: Regulatory Mechanisms and Emerging Directions. |
| Q92889614 | Cancer-associated cerebral infarction during direct oral anticoagulant treatment in cancer patients: a case series |
| Q41015901 | Cancer-related multiple brain infarctions caused by Trousseau syndrome in a patient with metastatic colon cancer: a case report |
| Q35483514 | Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome |
| Q89942065 | Case of internal jugular vein thrombosis and fever: Lemierre's syndrome or Trousseau's syndrome? |
| Q64965339 | Cerebral Thromboembolism after Lobectomy for Lung Cancer: Pathological Diagnosis and Mechanism of Thrombus Formation. |
| Q92524119 | Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma: A case report |
| Q57024822 | Cerebral infarction associated with benign mucin-producing adenomyosis: report of two cases |
| Q36759454 | Characteristics of cryptogenic stroke in cancer patients |
| Q91839670 | Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients |
| Q40898286 | Clinical features of subarachnoid hemorrhage in patients with positive cancer history |
| Q35221425 | Co-occurrence of multiple cerebral infarctions due to hypercoagulability associated with malignancy and meningeal carcinomatosis as the initial manifestation of gastric cancer |
| Q39307644 | Coagulation induced by C3aR-dependent NETosis drives protumorigenic neutrophils during small intestinal tumorigenesis. |
| Q38106603 | Colorectal cancer and hypercoagulability |
| Q37831798 | Contribution of platelets to tumour metastasis. |
| Q49578979 | Cumulative incidence, risk factors and prognostic impact of venous thromboembolism in Japanese patients with advanced gastric cancer |
| Q48869594 | Death causes in breast cancer patients |
| Q64263742 | Desmoplastic small round cell tumors: Multimodality treatment and new risk factors |
| Q38995634 | Diffuse Arterial Thrombosis as a First Manifestation of Occult Malignancy. |
| Q92409584 | Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies |
| Q40173427 | Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-associated hypercoagulation. |
| Q47828398 | Effects of magnesium sulphate on coagulation after laparoscopic colorectal cancer surgery, measured by rotational thromboelastometry (ROTEM® ). |
| Q26752352 | Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice |
| Q37242472 | Epidemiology of cancer-related venous thromboembolism |
| Q35843853 | Extensive Bilateral Lemierre Syndrome due to Methicillin-Resistant Staphylococcus epidermidis in a Patient with Lung Adenocarcinoma |
| Q42123245 | External Jugular Vein Thrombosis as a Sign of Metastatic Breast Cancer |
| Q45852873 | Familial risks of unusual forms of venous thrombosis: a nationwide epidemiological study in Sweden |
| Q38184560 | Fatal paraneoplastic embolisms in both circulations in a patient with poorly differentiated neuroendocrine tumour |
| Q57110804 | Gastric cancer with multiple intramural metastases and metastasis to the small intestine which eventually developed Trousseau's syndrome: report of a case |
| Q37784320 | Glycosaminoglycans and Activated Contact System in Cancer Patient Plasmas |
| Q38007880 | HIF-mediated endothelial response during cancer progression. |
| Q83757620 | Hemostatic abnormalities in dogs with carcinoma: a thromboelastographic characterization of hypercoagulability |
| Q84340525 | Hemostatic factors, innate immunity and malignancy |
| Q47989925 | Heparanase procoagulant activity, factor Xa, and plasminogen activator inhibitor 1 are increased in shift work female nurses |
| Q37500092 | Heparins attenuate cancer metastasis: are selectins the link? |
| Q33594318 | Idiopathic superficial thrombophlebitis and the incidence of cancer in primary care patients |
| Q45734083 | Idiopathic venous thromboembolism: a potential surrogate for occult cancer |
| Q93136725 | Immunotherapy-induced acute pulmonary thromboembolism: A case report |
| Q59806401 | Impacts of Cancer on Platelet Production, Activation and Education and Mechanisms of Cancer-Associated Thrombosis |
| Q64890806 | Increased RNA Expression of von Willebrand Factor Gene Is Associated With Infiltrating Lobular Breast Cancer and Normal PAM50 Subtype. |
| Q57141790 | Increased expression of von Willebrand factor gene is associated with poorer survival in primary lower grade glioma |
| Q34990141 | Integrative bioinformatics links HNF1B with clear cell carcinoma and tumor-associated thrombosis |
| Q38259585 | Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1. |
| Q92278677 | Ischemic lesions in all territories as a marker of malignant hypercoagulability |
| Q37903682 | Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes |
| Q38047401 | Lymph node infarction: role of underlying malignancy, tumour proliferation fraction and vascular compromise--a study of 35 cases and a comprehensive review of the literature |
| Q38436539 | Management of superficial vein thrombosis |
| Q55432473 | Mecanismos do tromboembolismo venoso no câncer: uma revisão da literatura. |
| Q37530613 | Mechanisms for the formation of membranous nanostructures in cell-to-cell communication. |
| Q47653261 | Microfluidic isolation of platelet-covered circulating tumor cells. |
| Q26783691 | Microparticles as Biomarkers of Blood Coagulation in Cancer |
| Q58695822 | Mitral valve nonbacterial thrombotic endocarditis: a rare multi-surgery-tolerant survivor of Trousseau's syndrome |
| Q33743421 | Modelling pulmonary microthrombosis coupled to metastasis: distinct effects of thrombogenesis on tumorigenesis |
| Q39335117 | Monitoring of anticoagulant therapy in cancer patients with thrombosis and the usefulness of blood activation markers |
| Q39119140 | Much More than Trousseau Syndrome. The Broad Spectrum of the Pancreatic Paraneoplastic Syndromes |
| Q39852199 | Mucins Carrying Selectin Ligands as Predictive Biomarkers of Disseminated Intravascular Coagulation Complication in ARDS |
| Q92609575 | Multifocal Thrombophlebitis and Orbital Cellulitis |
| Q57146588 | Multifocal cerebral infarction as the first manifestation of occult malignancy: Case series of trousseau's syndrome and literature review |
| Q41960834 | Multiple embolic cerebral infarcts as the first manifestation of metastatic ovarian cancer |
| Q35220883 | Multiple extra-ischemic hemorrhages following intravenous thrombolysis in a patient with Trousseau syndrome: case study |
| Q28066483 | NETosis in Cancer - Platelet-Neutrophil Crosstalk Promotes Tumor-Associated Pathology |
| Q36625405 | NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation |
| Q33957938 | NETosis: a new factor in tumor progression and cancer-associated thrombosis |
| Q38387142 | Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood |
| Q38784271 | Neutrophil extracellular traps: protagonists of cancer progression? |
| Q37307380 | New insights into cancer-associated thrombosis |
| Q37519054 | New oral anticoagulants and the cancer patient. |
| Q92129780 | Novel Aspects of Extracellular Vesicles as Mediators of Cancer-Associated Thrombosis |
| Q26775634 | Pancreatic cancer and thromboembolic disease, 150 years after Trousseau |
| Q39401169 | Paraneoplastic syndromes associated with gynecological cancers: A systematic review |
| Q34023610 | Paraneoplastic syndromes associated with lung cancer |
| Q90088570 | Paraneoplastic syndromes in lung cancer and their management |
| Q38129719 | Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond |
| Q91979012 | Pathophysiology 2: The Role of Platelets in Cancer Biology |
| Q92603378 | Patrolling the vascular borders: platelets in immunity to infection and cancer |
| Q55035236 | Pembrolizumab-induced acute thrombosis: A case report. |
| Q37812994 | Peripheral arterial ischemic events in cancer patients |
| Q35977197 | Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer |
| Q39062472 | Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occult cancer in patients with cryptogenic stroke |
| Q44522050 | Platelet Integrins in Tumor Metastasis: Do They Represent a Therapeutic Target? |
| Q55098679 | Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients. |
| Q47108876 | Platelet derived TGF-β promotes cervical carcinoma cell growth by suppressing KLF6 expression |
| Q38626563 | Platelet microparticles and cancer: An intimate cross-talk |
| Q33822598 | Platelet releasates promote the proliferation of hepatocellular carcinoma cells by suppressing the expression of KLF6 |
| Q38642475 | Platelet-derived Extracellular Vesicles: An Emerging Therapeutic Approach. |
| Q34294719 | Platelets and cancer: a casual or causal relationship: revisited. |
| Q35904932 | Platelets at the interface of thrombosis, inflammation, and cancer. |
| Q92650591 | Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy |
| Q37808901 | Platelets: linking hemostasis and cancer |
| Q87850468 | Pleiotropic effects of heparins: does anticoagulant treatment increase survival in cancer patients? |
| Q48291519 | Predictors of unknown cancer in patients with ischemic stroke. |
| Q39201228 | Preoperative plasma D-dimer level is an independent prognostic factor in patients with completely resected non-small cell lung cancer. |
| Q37989804 | Preventing venous thromboembolism in hospitalized patients with cancer: improving compliance with clinical practice guidelines |
| Q90220776 | Prognostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Head and Neck Malignancies |
| Q47109863 | Prognostic significance of preoperative plasma D-dimer level in patients with surgically resected clinical stage I non-small cell lung cancer: a retrospective cohort study |
| Q84068541 | Prostate-cancer-associated hypercoagulability: do we need to worry about androgen deprivation? |
| Q36074707 | Pulmonary Venous Obstruction in Cancer Patients |
| Q37587189 | Pulmonary embolism in non-brain tumor patients after surgery-a retrospective study in China |
| Q26827098 | Pulmonary tumor thrombotic microangiopathy: report of 3 cases and review of the literature |
| Q45774863 | Rapidly progressive symptom development of pulmonary arterial hypertension: a case report of Trousseau syndrome |
| Q39879015 | Recurrent Venous Thromboembolism in Two Patients With Cancer Taking Rivaroxaban |
| Q24650849 | Recurrent thromboflebitis as a warning sign for cancer: a case report |
| Q33734780 | Regulation of tumor growth and metastasis: the role of tumor microenvironment |
| Q64912164 | Right ventricular mobile thrombus in end-stage hypertrophic cardiomyopathy. |
| Q49873887 | Risk and incidence of perioperative deep vein thrombosis in patients undergoing gastric cancer surgery |
| Q33606182 | Risk factors and prognosis of pulmonary embolism in patients with lung cancer |
| Q34052232 | Role of factor xa inhibitors in cancer-associated thrombosis: any new data? |
| Q55464074 | Role of the tissue factor pathway in the biology of tumor initiating cells. |
| Q45970943 | SPRR2A expression in cholangiocarcinoma increases local tumor invasiveness but prevents metastasis. |
| Q90613677 | Salvage surgery for primary lung cancer complicated with Trousseau's syndrome after chemotherapy: a case report |
| Q37481868 | Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells |
| Q90732621 | Severe Fatal Systemic Embolism Due to Non-Bacterial Thrombotic Endocarditis as the Initial Manifestation of Gastric Adenocarcinoma: Case Report |
| Q38620799 | Sialic acids in cancer biology and immunity. |
| Q36908164 | Sialic acids in human health and disease |
| Q37726758 | Silent pulmonary thromboembolism in neurosurgery patients: Report of 2 cases and literature review |
| Q48264231 | Simultaneous occurrence of myocardial infarction and duodenal perforation. |
| Q92970630 | Stroke Rate Increases Around the Time of Cancer Diagnosis |
| Q86037979 | Stroke and Cancer- A Complicated Relationship |
| Q50055788 | Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage |
| Q36226124 | Synchronous primary corpus and ovarian cancer: High incidence of endometriosis and thrombosis |
| Q92254452 | The D-dimer level predicts the postoperative prognosis in patients with non-small cell lung cancer |
| Q59335689 | The Platelet Response to Tissue Injury |
| Q49424955 | The Potential Role of Senescence As a Modulator of Platelets and Tumorigenesis |
| Q85205795 | The impact of bortezomib on the risk of thrombosis in multiple myeloma |
| Q59074701 | The incidence and predictors of thromboembolic events in patients with lung cancer |
| Q37374557 | The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. |
| Q37208791 | The multiplex bead array approach to identifying serum biomarkers associated with breast cancer |
| Q38840361 | The polyphosphate/factor XII pathway in cancer-associated thrombosis: novel perspectives for safe anticoagulation in patients with malignancies. |
| Q38017369 | The protein C pathway in cancer metastasis |
| Q37740299 | The role of activated protein C in cancer progression |
| Q46815106 | The role of mucin-educated platelet activation in tumor invasiveness: An unfolding concern in the realm of cancer biology |
| Q37242670 | The role of platelet activation in tumor metastasis. |
| Q91657099 | Three Territory Sign: An MRI marker of malignancy-related ischemic stroke (Trousseau syndrome) |
| Q48179209 | Three-Territory DWI Acute Infarcts: Diagnostic Value in Cancer-Associated Hypercoagulation Stroke (Trousseau Syndrome). |
| Q53657513 | Thromboembolic Events in Malignant Pleural Mesothelioma. |
| Q41082035 | Thrombosis in an Internal Jugular Vein and an Upper Limb Deep Vein Treated with Edoxaban |
| Q33592102 | Tissue factor and PAR2 signaling in the tumor microenvironment |
| Q38048550 | Tissue factor and cancer |
| Q37903955 | Tissue factor and cell signalling in cancer progression and thrombosis |
| Q39624307 | Tissue factor as a novel marker for detection of circulating cancer cells |
| Q46058011 | Total palliative care for a patient with multiple cerebral infarctions that occurred repeatedly in association with gastric cancer (Trousseau's syndrome). |
| Q90403157 | Treatment of EGFR mutation-positive non-small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report |
| Q90448603 | Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria |
| Q41931292 | Trousseau syndrome |
| Q61807340 | Trousseau syndrome in a patient with advanced oral squamous cell carcinoma: a case report |
| Q42315003 | Trousseau syndrome presenting with penile gangrene |
| Q33795243 | Trousseau's Syndrome Caused by Intrahepatic Cholangiocarcinoma: An Autopsy Case Report and Literature Review |
| Q49963505 | Trousseau's Syndrome Causing Refractory Deep Venous Thrombosis |
| Q36852800 | Trousseau's Syndrome in Cholangiocarcinoma: The Risk of Making the Diagnosis |
| Q41872549 | Trousseau's Syndrome, a Previously Unrecognized Condition in Acute Ischemic Stroke Associated With Myocardial Injury |
| Q91791948 | Trousseau's syndrome associated with pulmonary pleomorphic carcinoma exhibiting aggressive features: A case report |
| Q37407364 | Trousseau's syndrome caused by bladder cancer producing granulocyte colony-stimulating factor and parathyroid hormone-related protein: A case report |
| Q41965622 | Trousseau's syndrome in a patient with advanced stage gastric cancer |
| Q46191941 | Trousseau's syndrome in a patient with gastric cancer |
| Q89451807 | Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient |
| Q37438142 | Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. |
| Q37169096 | Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients |
| Q33710071 | Tumors, ticks and tissue factor |
| Q33787397 | Unexpected outcome from Trousseau syndrome |
| Q48009155 | Unlocking Aspirin's Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. |
| Q26782483 | Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence |
| Q38139899 | Update on clinical and mechanistic aspects of paraneoplastic syndromes |
| Q38944457 | Venous Thromboembolism in Patients Diagnosed With Lung Cancer |
| Q24631121 | Venous thromboembolic disease |
| Q37088527 | Venous thromboembolic events and organ-specific occult cancers: a review and meta-analysis |
| Q37416512 | Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors |
| Q37688960 | Venous thromboembolism and cancer: a systematic review |
| Q30436810 | Venous thromboembolism in malignant gliomas |
| Q26996508 | Venous thromboembolism in the cancer population: pathology, risk, and prevention |
| Q35584421 | What do prostate cancer patients die of? |
| Q83894145 | [Stroke in cancer patients. A paraneoplastic neurological syndrome?] |
| Q84700920 | [Supportive therapy of urogenital tumors: diagnostic and therapy of common complications] |
| Q39036055 | miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells |
| Q64069245 | von Willebrand Factor Gene Expression in Primary Lower Grade Glioma: Mutually Co-Occurring Mutations in von Willebrand Factor, ATRX, and TP53 |
Search more.